Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion [0.03%]
订正：联合模型量化allo干细胞移植后免疫细胞动力学与异体免疫事件以及后续供者淋巴细胞输注之间的关联
Eva A S Koster,Edouard F Bonneville,Peter A von dem Borne et al.
Eva A S Koster et al.
[This corrects the article DOI: 10.3389/fimmu.2023.1208814.]. Keywords: T-cell depletion; T-cell kinetics; a...
Published Erratum
Frontiers in immunology. 2025 Jun 13:16:1637094. DOI:10.3389/fimmu.2025.1637094 2025
Correction: Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study [0.03%]
纠正：在评估胃癌患者预后和免疫治疗疗效方面ARID1A相关免疫基因风险模型的建立与验证：一项转化研究
Jiangtao Zhang,Jingting Li,Shangfeng Yang et al.
Jiangtao Zhang et al.
[This corrects the article DOI: 10.3389/fimmu.2025.1541491.]. Keywords: ARID1A; gastric cancer; immune gene ...
Published Erratum
Frontiers in immunology. 2025 Jun 13:16:1637370. DOI:10.3389/fimmu.2025.1637370 2025
Corrigendum: 17β-Estradiol promotes trained immunity in female against sepsis via regulating nucleus translocation of RelB [0.03%]
雌激素通过调控RelB核转位促进训练免疫对抗脓毒症发表更正：雌激素通过调控RelB核转位促进训练免疫对抗脓毒症
Zhiheng Sun,Yuchen Pan,Junxing Qu et al.
Zhiheng Sun et al.
[This corrects the article DOI: 10.3389/fimmu.2020.01591.]. Keywords: estradiol; gender difference; macropha...
Published Erratum
Frontiers in immunology. 2025 Jun 13:16:1629629. DOI:10.3389/fimmu.2025.1629629 2025
Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series [0.03%]
乌立单抗换药机制研究：个例研究报告系列的更正公告
Regina Berkovich,Jonathan Calkwood,Heidi Crayton et al.
Regina Berkovich et al.
[This corrects the article DOI: 10.3389/fimmu.2025.1527102.]. Keywords: B-cell depletion; anti-CD20; disabil...
Published Erratum
Frontiers in immunology. 2025 Jun 13:16:1609054. DOI:10.3389/fimmu.2025.1609054 2025
Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategies [0.03%]
论著：精准肿瘤学数据的临床应用以指导个体化和免疫治疗为基础的治疗策略
Nicholas A Young,Jenifer R Prosperi,Aharon G Freud et al.
Nicholas A Young et al.
Graphical summary. Keywords: drug sensitivity testing; immunotherapy; individualized patient treatment; mole...
X-linked lymphoproliferative disease type 1: a clinical and genetic update [0.03%]
X连锁淋巴增生性疾病1型的临床和基因更新
Jiaxun Li,Luyu Lv,Qingqing Wei et al.
Jiaxun Li et al.
X-linked lymphoproliferative disease (XLP), also known as Duncan's disease, is a primary immunodeficiency disorder linked to the X chromosome. In 1998, SH2D1A, which encodes the signaling lymphocyte activation molecule (SLAM)-associated pro...
Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer treatment [0.03%]
内皮抑素抗血管生成治疗与免疫调节：机制及联合用药的协同潜力和癌症治疗中的作用
JingTao Sun,Simeng Ren,QingYun Zhao et al.
JingTao Sun et al.
Cancer remains a critical global health challenge, driven by tumor angiogenesis and immune evasion. Endostatin, a collagen XVIII-derived fragment, uniquely suppresses angiogenesis and reprograms the immunosuppressive tumor microenvironment ...
Anush Martirosyan,Eva Kriegova,Gayane Manukyan
Anush Martirosyan
Antiphospholipid syndrome (APS) is a systemic autoimmune condition characterized by the persistent presence of antiphospholipid antibodies (aPL), and is commonly associated with thrombosis and pregnancy-related complications. To date, relat...
Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer [0.03%]
单细胞和批量RNA测序数据的综合分析揭示了预测泛癌免疫治疗反应和预后的EGFR谱型
Changchun Ye,Xiaoya Chen,Zilu Chen et al.
Changchun Ye et al.
Introduction: Immune checkpoint inhibitors (ICIs) have changed the paradigm of cancer treatment, but their effectiveness in some patients with epidermal growth factor receptor (EGFR) mutations is unsatisfactory. Therefore...
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation [0.03%]
锻炼动员的供者淋巴细胞输注联合细胞因子刺激用于预防和治疗allo-HSCT后白血病复发
London M McDougal,Forrest L Baker,Michael P Gustafson et al.
London M McDougal et al.
Donor lymphocyte infusions (DLI) are a standard therapy following allogeneic hematopoietic cell transplantation (alloHCT) for preventing and treating leukemic relapse in high-risk patients, particularly those with myeloid malignancies such ...